Alembic Pharmaceuticals announced the first prescription-based sale of its branded antibiotic, Pivya® (pivmecillinam) tablets, in the United States. This marks a significant milestone as it is Alembic’s first branded pharmaceutical product launched in the US market via its subsidiary, Alembic Therapeutics LLC. Pivya® is indicated for treating uncomplicated urinary tract infections (uUTIs) in women, addressing a segment that has seen limited new product introductions.
First Prescription Sale in the US Market
Alembic Pharmaceuticals Limited announced on 6th March 2026 that its step-down wholly owned subsidiary, Alembic Therapeutics LLC, has recorded its initial prescription-based sale of Pivya® (pivmecillinam) tablets in the United States. This follows the recent commercial launch of the product.
Pivya® is a first-line oral antibiotic option specifically for the treatment of uncomplicated urinary tract infections (uUTIs) in women. Alembic identifies this as a large and stable therapeutic segment, accounting for approximately 30 million prescriptions annually in the US, where new product introductions have been limited for over a decade.
Strategic Milestone and Portfolio Building
Mr. Pranav Amin, Managing Director of Alembic Pharmaceuticals Limited, stated that the commercial launch of Pivya® represents an “important milestone” as the company enters the US branded pharmaceuticals market. This product launch is the first step in Alembic’s strategy to build a focused branded specialty portfolio in the US.
Pivya® contains pivmecillinam, a penicillin-class antibacterial agent, indicated for uUTIs caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.
Commercial and Strategic Context
Alembic has established an initial sales footprint across key US territories, targeting high-prescribing physicians in women’s health. The company plans a phased expansion of its field force as prescription momentum builds.
The launch reinforces Alembic’s balanced approach to expanding its presence in the US market, complementing its established generics franchise with specialty and branded pharmaceuticals. The subsidiary, Alembic Therapeutics LLC, focuses on delivering high-quality medicines emphasizing Quality, Reliability, and Access.
Source: BSE
